ライフサイエンスコーパス: mastectomy

1 ssected specimens from 7 patients undergoing mastectomy.

2 over time and are now similar to those after mastectomy.

3 s, and 25 cancers discovered at prophylactic mastectomy.

4 teral breast warrant discussion of bilateral mastectomy.

5 herapy decreases the likelihood of LRR after mastectomy.

6 event for breast cancer patients undergoing mastectomy.

7 Contralateral prophylactic mastectomy.

8 ion is increasingly performed at the time of mastectomy.

9 ant treatment option for patients undergoing mastectomy.

10 reast cancer, many women continue to undergo mastectomy.

11 with early-stage breast cancer who underwent mastectomy.

12 ubtypes) with breast conservation therapy or mastectomy.

13 but 31% of BCT-eligible patients still chose mastectomy.

14 ectomy, breast reconstruction, and bilateral mastectomy.

15 total of 35.5% of the study cohort underwent mastectomy.

16 underwent breast-conserving surgery (BCS) or mastectomy.

17 s and reexcision among patients with partial mastectomy.

18 03-1.29) influenced axillary evaluation with mastectomy.

19 fter surgeons had completed standard partial mastectomy.

20 l after breast conservation therapy (BCT) vs mastectomy.

21 on lumpectomy and 28,267 (37.9%) underwent a mastectomy.

22 breast cancer detected during a prophylactic mastectomy.

23 breast cancer (58.3%) underwent a bilateral mastectomy.

24 d breast tissue from six patients undergoing mastectomy.

25 iate grade, ER/PR positivity, and receipt of mastectomy.

26 s; n = 2108); complications were common with mastectomy.

27 hundred ninety-four women (22.4%) underwent mastectomy.

28 rence (IBTR), yielding comparable results to mastectomy.

29 th invasive breast cancer undergoing planned mastectomy.

30 dely clear margins is common and may lead to mastectomy.

31 ction to decrease breast complications after mastectomy.

32 onstructive surgery with patients undergoing mastectomy.

33 ogous IR, DR, and SR breast procedures after mastectomy.

34 mastectomies, and contralateral prophylactic mastectomies.

35 tients (5%) underwent bilateral prophylactic mastectomy; 1,004 chose surveillance with (n = 173) or w

36 ) underwent BCS while 9011 (25.3%) underwent mastectomy; 17.7% undergoing BCS and 63.0% undergoing ma

37 Rates of ALND decreased in women undergoing mastectomy (2006, 20.0%; 2012, 10.7%) and BCS (2006, 1.2

38 axillary evaluation increased over time with mastectomy (2006, 56.6%; 2012, 67.4%) and were relativel

39 ata that included 28,176 women who underwent mastectomy (25,141 mastectomy alone and 3,035 IBR) betwe

40 n: 593 were reexcisions (14.4%) and 132 were mastectomies (3.2%).

41 Of non-genitoplasty titles, 35 were mastectomy, 6 mammoplasty, 21 facial feminization, and 3

42 Of 891 mastectomies, 65% (580/891) had immediate implant, 11% (

43 After mastectomy, 73.4% of the patients in both groups underwe

44 ian 4.5 vs 3.1 cm, P < 0.001) and receipt of mastectomy (81.4% vs 52.2%, P < 0.001) when compared to

45 e hernia repairs (15.7%), bariatric (10.5%), mastectomy (9.7%), and cholecystectomy (9.0%).

46 uding the cancers discovered at prophylactic mastectomy (95% confidence interval: 69.5%, 82.4%) and 9

47 at more than 24 months, 28 (6.4%) underwent mastectomy (all benign), and 68 (15.6%) had lesion upgra

48 a higher survival rate than those undergoing mastectomy alone (hazard ratio, 1.31; P < .001) or maste

49 3 or greater (HR 1.94, 95% CI 1.04-3.63) or mastectomy alone (HR 2.14, 95% CI 1.26-3.63).

50 ficantly increased odds of IBR compared with mastectomy alone (odds ratio [OR], 1.71; 95% CI, 1.47 to

51 tly farther compared with those who received mastectomy alone (OR, 1.04; 95% CI, 1.02 to 1.05 for eve

52 8,176 women who underwent mastectomy (25,141 mastectomy alone and 3,035 IBR) between April 1, 2002, a

53 rvival rate compared with those treated with mastectomy alone or mastectomy with radiation for early-

54 n therapy was used to treat 70% of patients, mastectomy alone was used to treat 27% of patients, and

55 vival rates of patients who underwent BCT, a mastectomy alone, or a mastectomy with radiation were 97

56 of local therapy, breast-conserving therapy, mastectomy alone, or mastectomy followed by postmastecto

57 invasive ductal carcinoma treated with BCT, mastectomy alone, or mastectomy with radiation during th

58 Breast conservation therapy, mastectomy alone, or mastectomy with radiation.

59 o breast cancer for patients undergoing BCT, mastectomy alone, or mastectomy with radiation.

60 immediate breast reconstruction compared to mastectomy alone.

61 increase the risk of lymphedema compared to mastectomy alone.

62 Receipt of bilateral mastectomy also increased: from 3% in 1998 to 18% in 200

63 lumpectomy and radiation and underwent fewer mastectomies and less chemotherapy than patients with ca

64 estionnaires; of those eligible, 3,977 had a mastectomy and 1,598 reported receipt of CPM.

65 eceived CPM, while 45.8% received unilateral mastectomy and 22.8% received breast conservation surger

66 iopsy confirmed breast cancer, she underwent mastectomy and axillary node dissection for a left-sided

67 iopsy confirmed breast cancer, she underwent mastectomy and axillary node dissection for a left-sided

68 s incur potential morbidity, especially when mastectomy and breast reconstruction are done for widesp

69 Women undergoing mastectomy and breast reconstruction for unilateral brea

70 Patients aged 18-75 years who had undergone mastectomy and had at least four positive axillary lymph

71 Breast reconstruction at any time after mastectomy and patient satisfaction with different aspec

72 ccessful implant-based reconstructions after mastectomy and radiotherapy.

73 ile 175 (46%) did not receive PMRT following mastectomy and were followed over a median of 5.2 years

74 ew board approval, patients undergoing total mastectomy and/or axillary lymph node dissection were ra

75 lumpectomy, unilateral mastectomy, bilateral mastectomy) and rates of additional surgery after initia

76 Most NAC recipients (68.4%) had mastectomies, and 14.3% of them underwent BLM.

77 illary investigations, wait time to surgery, mastectomies, and contralateral prophylactic mastectomie

78 nserving surgery, 33.4% underwent unilateral mastectomy, and 7.0% underwent CPM.

79 rgoing breast-conserving surgery, unilateral mastectomy, and CPM.

80 ss than 2 mm alone are not an indication for mastectomy, and factors known to impact rates of IBTR sh

81 Salpingo-oophorectomy and/or mastectomy are currently the only effective options offe

82 Medical indications for mastectomy are well defined and present in a minority of

83 Mastectomies as first salvage treatment for ipsilateral

84 mes of immediate breast reconstruction after mastectomy at 11 leading medical centers.

85 ts (9.6%) underwent a bilateral prophylactic mastectomy at a median of 23 months following EOC diagno

86 e cross-sectional study of patients planning mastectomy at a single site, over 20 months.

87 Of 485 patients reporting mastectomy at the initial survey and remaining disease f

88 diotherapy use for DCIS had increased use of mastectomy at the time of a second breast event even amo

89 The rate of positive margins after partial mastectomy (before randomization) was similar in the sha

90 and those undergoing bilateral prophylactic mastectomies between 1980 and 2009.

91 atients with breast cancer who underwent 891 mastectomies between 2005 and 2013 were prospectively sc

92 l surgical procedure (lumpectomy, unilateral mastectomy, bilateral mastectomy) and rates of additiona

93 sting and the impact of results on bilateral mastectomy (BLM) use.

94 , breast conserving surgery (BCS), bilateral mastectomy (BLM), and unilateral mastectomy (ULM) was ab

95 survival compared with patients who received mastectomy, both in noncarriers (hazard ratio [HR] = 0.9

96 The goal of post-mastectomy breast reconstruction is to restore body imag

97 ried widely between hospitals following post-mastectomy breast reconstruction.

98 portions of BCS-eligible patients undergoing mastectomy, breast reconstruction, and bilateral mastect

99 patients (4.9%) had a subsequent completion mastectomy, but no difference was found in the type of r

100 restore body image and quality-of-life after mastectomy, but removal of the nipple-areolar complex ma

101 on with implants or expanders at the time of mastectomy-but there is a lack of high-quality evidence

102 After mastectomy chest-wall radiotherapy was associated with i

103 cers detected by imaging and/or prophylactic mastectomy compared with physical findings were more lik

104 patients choosing contralateral prophylactic mastectomy, complications and procedure extent may be un

105 e growing rate of contralateral prophylactic mastectomy (CPM) among women diagnosed as having breast

106 process regarding contralateral prophylactic mastectomy (CPM) among women with sporadic breast cancer

107 ients who undergo contralateral prophylactic mastectomy (CPM) and breast reconstruction.

108 emporal trends in contralateral prophylactic mastectomy (CPM) and determine whether survival differed

109 lines assert that contralateral prophylactic mastectomy (CPM) should be discouraged in patients witho

110 Contralateral prophylactic mastectomy (CPM) use is increasing among women with unil

111 The use of contralateral prophylactic mastectomies (CPMs) among patients with invasive unilate

112 The rate of contralateral prophylactic mastectomies (CPMs) continues to rise, although there is

113 k women and mutation carriers, risk-reducing mastectomy decreased breast cancer by 85% to 100% and br

114 ter mastectomy was considered delayed if the mastectomy did not include IR or secondary if the mastec

115 pe of surgery performed-breast-conserving or mastectomy-did not influence rates of LR and RR.

116 ast-conserving therapy, mastectomy alone, or mastectomy followed by postmastectomy radiation therapy

117 Patients receiving mastectomy followed by radiotherapy had prognostically w

118 ryA 63-year-old woman with a history of left mastectomy for breast cancer and partial gastrectomy wit

119 Most women undergoing mastectomy for breast cancer do not undergo breast recon

120 bed complications in 14,894 women undergoing mastectomy for breast cancer from 1998 to 2007 and who u

121 reexcision among patients undergoing partial mastectomy for breast cancer.

122 Immediate breast reconstruction (IBR) after mastectomy for cancer has increased in recent years, yet

123 t study of temporal trends in performance of mastectomy for early-stage breast cancer using multivari

124 t for prophylactic mastectomy or therapeutic mastectomy for in situ breast cancer (78.6%; P < .001).

125 therapy provides an appealing alternative to mastectomy for many women.

126 ), P < 0.001), and to require re-excision or mastectomy for margin clearance (17/196 (8.7%) vs. 47/20

127 onservation is therapeutically equivalent to mastectomy for most patients with early-stage breast can

128 ology clinic among women planning to undergo mastectomy for stage I to III invasive ductal or lobular

129 ividual surgeon influences the likelihood of mastectomy for the treatment of localized breast cancer.

130 oved outcomes, increasing rates of bilateral mastectomy for unilateral cancer have been observed in t

131 Rates of bilateral mastectomy for unilateral disease increased from 1.9% in

132 rends in breast reconstruction and bilateral mastectomy for unilateral disease.

133 with stage I to III breast cancer undergoing mastectomy from 2000 through 2011.

134 and 1-3 positive lymph nodes, who underwent mastectomy from 2004 to 2015.

135 ncluded women aged 18 to 64 years undergoing mastectomy from January 1, 2004, through December 31, 20

136 y; 17.7% undergoing BCS and 63.0% undergoing mastectomy had an axillary evaluation.

137 Patients undergoing mastectomy had larger tumors and higher proportions of p

138 the number of women undergoing risk-reducing mastectomy has increased rapidly in the USA in the past

139 mortality difference compared with bilateral mastectomy (HR, 1.02 [95% CI, 0.94-1.11]; 10-year mortal

140 nserving therapy was performed in 656 (39%), mastectomy in 297 (17%) and mastectomy + postmastectomy

141 A minority of patients undergoing mastectomy in a single academic center made a high-quali

142 The adjusted odds of mastectomy in BCS-eligible women increased 34% during th

143 ere seen in the trials of radiotherapy after mastectomy in node-positive disease (rate ratios, breast

144 I, 0.62 to 0.65), whereas radiotherapy after mastectomy in node-positive disease was associated with

145 ecent shift toward increasing performance of mastectomy in patients eligible for BCS.

146 s of radiotherapy for DCIS affect the use of mastectomy in these patients.

147 Women undergoing mastectomy in this sample were highly involved in decisi

148 ctomy did not include IR or secondary if the mastectomy included IR.

149 A mastectomy, including post-anaesthesia recovery and inpa

150 mong 189,734 patients, the rate of bilateral mastectomy increased from 2.0% (95% CI, 1.7%-2.2%) in 19

151 Use of bilateral mastectomy increased significantly throughout California

152 perience a second breast event, many undergo mastectomy instead.

153 Evidence indicates that increasing use of mastectomy is a patient-driven trend that is most pronou

154 are eligible for mastectomy, nipple-sparing mastectomy is a reasonable approach.

155 For patients with germline TP53 mutations, mastectomy is advised; radiation therapy is contraindica

156 Bilateral mastectomy is increasingly used to treat unilateral brea

157 fit of testosterone therapy (with or without mastectomy) is a reduced risk of breast cancer.

158 erentially around the cavity left by partial mastectomy) may reduce the rates of positive margins (ma

159 derate-penetrance genes who are eligible for mastectomy, nipple-sparing mastectomy is a reasonable ap

160 associated with more local recurrences than mastectomy, no differences in overall survival have been

161 ith additional procedure matching: bilateral mastectomy, nodal surgery, tissue, and/or implant.

162 ) after receiving either: (1) nipple-sparing mastectomy (NSM) or (2) simple mastectomy with subsequen

163 Mastectomy only and mastectomy with reconstruction.

164 6.2%) and did not differ by treatment group (mastectomy only, 55.2% [15.0%]; mastectomy with reconstr

165 my only; 39 of these women (47.6%) underwent mastectomy only.

166 7%) had a calculated treatment preference of mastectomy only; 39 of these women (47.6%) underwent mas

167 ed for this study, including 6 who underwent mastectomy or axillary node dissection.

168 Cohort characteristics were grouped by mastectomy or BCS.

169 ed that receipt of CPM (vs either unilateral mastectomy or breast conservation surgery) was significa

170 dual surgeons and institutions on the use of mastectomy or breast conserving surgery (BCS) among elde

171 ed node-negative breast cancers treated with mastectomy or lumpectomy and radiation enrolled in the S

172 unilateral breast cancer who had undergone a mastectomy or lumpectomy with clear surgical margins.

173 o previous history of bilateral prophylactic mastectomy or ovarian cancer, at least 2 months of follo

174 d the increase was greatest for prophylactic mastectomy or therapeutic mastectomy for in situ breast

175 58 ex vivo samples from patients undergoing mastectomy or wide local excision, we demonstrate the pe

176 .7; P < .001), patients undergoing bilateral mastectomy (OR, 0.5; P < .001), or patients in the highe

177 % CI, 1.62-1.85), contralateral prophylactic mastectomy (OR, 1.48; 95% CI, 1.23-1.77), and a greater

178 tatic disease (OR, 1.51; 95% CI, 1.42-1.61), mastectomy (OR, 1.73; 95% CI, 1.62-1.85), contralateral

179 self-report, categorized as CPM, unilateral mastectomy, or breast conservation surgery.

180 tion (breast-conserving therapy), unilateral mastectomy, or CPM, with subsequent subgroup analysis st

181 2 (51.2%) of 160 noncarriers chose bilateral mastectomy (P < .001).

182 ower case volume were more likely to perform mastectomy (P < 0.05).

183 ed by a decrease in unilateral and bilateral mastectomy (P = .002).

184 Women who had a partial mastectomy (P=0.028), had a higher educational level (P=

185 Data from 12 BCS patients and the 7 mastectomy patients served to build a set of images for

186 ients compared with only 16.0% of unilateral mastectomy patients, with rates of reconstruction with C

187 Conclusion At 1 year after mastectomy, patients who underwent autologous reconstruc

188 intestinal tract endoscopy (PFS, 26.5-34.3), mastectomy (PFS, 16.5-35.0), inguinal hernia repair (PFS

189 shave margins (CSM) versus standard partial mastectomy (PM) in patients with breast cancer.

190 undergoing 5 outpatient procedures: partial mastectomy (PM), partial mastectomy with sentinel lymph

191 in breast cancer patients undergoing partial mastectomy (PM).

192 clinical factors, surgical approach (partial mastectomy [PM] or total mastectomy [TM]), and BCT failu

193 ed in 656 (39%), mastectomy in 297 (17%) and mastectomy + postmastectomy radiation therapy in 744 (44

194 C should not be the sole indication for post-mastectomy radiation, and accelerated delivery methods f

195 r nearly all previously irradiated skin plus mastectomy ("radical").

196 Unadjusted rates of mastectomy ranged from 0% in the bottom quintile of surg

197 A lower overall salvage mastectomy rate after LR was observed in the LE+RT group

198 To study the impact of rising bilateral mastectomy rates among neoadjuvant chemotherapy (NAC) re

199 Multiple studies have demonstrated growth in mastectomy rates and concurrent increase in PMR utilizat

200 ence showed that MRI significantly increased mastectomy rates and suggests an unfavorable harm-benefi

201 Mastectomy rates do not yet exceed current American Canc

202 y and is associated with positive margin and mastectomy rates that are low irrespective of the presen

203 Total mastectomy rates were 18% (31 of 176) in the MRI arm and

204 surgical outcome (positive margin rates and mastectomy rates) of women with breast cancer who underw

205 , and surgical outcomes (positive margin and mastectomy rates) were investigated.

206 In women undergoing mastectomy, rates of breast reconstruction increased fro

207 ribution of procedure types at the different Mastectomy Reconstruction Outcomes Consortium Study cent

208 The Mastectomy Reconstruction Outcomes Consortium Study is a

209 We performed a secondary analysis of the Mastectomy Reconstruction Outcomes Consortium study, a m

210 1, 2016, at the 11 sites associated with the Mastectomy Reconstruction Outcomes Consortium Study.

211 Breast-conserving therapy (BCT) and mastectomy result in equivalent long-term survival.

212 skin dimpling, and skin discoloration of the mastectomy scar and radiation bed.

213 egional lymph nodes, followed by an optional mastectomy scar boost of four fractions of 3.33 Gy.

214 Prophylactic mastectomy should be considered on an individual basis g

215 Women with SLN metastases who will undergo mastectomy should be offered ALND.

216 g BCS and uncertainty regarding its use with mastectomy, SLNB or ALND is performed frequently.

217 breast cancer was detected in a prophylactic mastectomy specimen.

218 ng and not including cancers in prophylactic mastectomy specimens, respectively).

219 on breast tissues excised from prophylactic mastectomy specimens.

220 l surgeon (MOR 1.97) had a greater impact on mastectomy than did the institution (MOR 1.71) or all ot

221 Beyond prophylactic mastectomy, there are currently very few options availab

222 l approach (partial mastectomy [PM] or total mastectomy [TM]), and BCT failure (initial PM followed b

223 on carriers) frequently undergo prophylactic mastectomy to minimize their risk of breast cancer.

224 re (including diagnostics, chemotherapy, and mastectomy) totalled US$1393.

225 Mastectomy type was not a significant predictor of compl

226 , bilateral mastectomy (BLM), and unilateral mastectomy (ULM) was abstracted from the medical records

227 r treatments combined, (2) CPM vs unilateral mastectomy (UM), and (3) CPM vs breast-conserving surger

228 Contralateral prophylactic mastectomy use is substantial among patients without cli

229 ographic factors that increase likelihood of mastectomy use.

230 Mastectomy vs BCS at a second breast event defined as DC

231 r DCIS increased the likelihood of receiving mastectomy vs BCS at a subsequent breast event, even amo

232 Mastectomy was associated with 90% to 100% reduction in

233 ty, 16.8% [95% CI, 16.6%-17.1%]), unilateral mastectomy was associated with higher all-cause mortalit

234 Unilateral mastectomy was associated with higher mortality than wer

235 In M0 patients, mastectomy was associated with worse survival outcomes c

236 Reconstruction more than 7 days after mastectomy was considered delayed if the mastectomy did

237 Reconstruction within 7 days of mastectomy was considered immediate.

238 Bilateral mastectomy was more often used by non-Hispanic white wom

239 95% CI, 1.04-1.22]); in contrast, unilateral mastectomy was more often used by racial/ethnic minoriti

240 Mastectomy was once the gold standard for the treatment

241 Mastectomy was performed in 1464 patients and breast-con

242 Mastectomy was performed in 17293 women (mean [SD] age,

243 Lumpectomy or mastectomy was performed in 71 women (79 index malignanc

244 Mastectomies were categorized as immediate implant, imme

245 Adjusted odds ratios for receiving mastectomy were 1.43 (95% CI, 1.10-1.85) and 1.90 (95% C

246 -1, M0) after breast conservation surgery or mastectomy were eligible.

247 ergoing no secondary procedures unrelated to mastectomy were included.

248 Patients receiving bilateral mastectomy were more likely to receive reconstruction (o

249 patients undergoing unilateral or bilateral mastectomy were recorded.

250 n increasing number of patients are pursuing mastectomy, which may be followed by breast reconstructi

251 vised placement of an implant at the time of mastectomy while Surgeon B contrasted the pros and cons

252 al carcinoma in situ (DCIS) who will undergo mastectomy, who previously underwent breast and/or axill

253 h ductal carcinoma in situ, who will undergo mastectomy, who previously underwent breast and/or axill

254 Thirty-eight underwent mastectomy/wide excision with partial skin resection ("c

255 In contrast, 47.9% aCT patients had mastectomies with 7.3% BLM.

256 4, and June 30, 2016, 2108 patients had 2655 mastectomies with immediate implant-based breast reconst

257 ther unilateral (47.2%) or bilateral (52.8%) mastectomies with reconstruction.

258 r presenting for breast reconstruction after mastectomy with 2 years or more of follow-up.

259 bidity were decreased in patients undergoing mastectomy with and without immediate breast reconstruct

260 Her breast surgeon recommended a right mastectomy with axillary node dissection.

261 of patients for whom RT could be avoided or mastectomy with breast reconstruction is indicated.

262 o its independent effects on morbidity after mastectomy with immediate breast reconstruction are limi

263 ve cohort study of adult women who underwent mastectomy with immediate breast reconstruction from 200

264 g surgery and nipple-sparing or skin-sparing mastectomy with immediate breast reconstruction, and to

265 le were women with breast cancer planned for mastectomy with immediate IBBR.

266 s of superior aesthetics for NSM over simple mastectomy with nipple reconstruction in immediate IBBR,

267 All women undergoing mastectomy with or without immediate breast reconstructi

268 upports the safety of NC in women undergoing mastectomy with or without immediate breast reconstructi

269 nt chemotherapy for surgical morbidity after mastectomy with or without reconstruction using 1:1 matc

270 ruction after nipple-sparing or skin-sparing mastectomy with planned radiotherapy should be addressed

271 tomy alone (hazard ratio, 1.31; P < .001) or mastectomy with radiation (hazard ratio, 1.47; P < .001)

272 inoma treated with BCT, mastectomy alone, or mastectomy with radiation during the period from 1998 to

273 with those treated with mastectomy alone or mastectomy with radiation for early-stage invasive ducta

274 alone was used to treat 27% of patients, and mastectomy with radiation was used to treat 3% of patien

275 who underwent BCT, a mastectomy alone, or a mastectomy with radiation were 97%, 94%, and 90%, respec

276 t conservation therapy, mastectomy alone, or mastectomy with radiation.

277 atients undergoing BCT, mastectomy alone, or mastectomy with radiation.

278 tment group (mastectomy only, 55.2% [15.0%]; mastectomy with reconstruction, 60.5% [16.5%]).

279 Among patients receiving mastectomy with reconstruction, reconstruction type and

280 specifically, within the subgroup undergoing mastectomy with reconstruction, using multivariable line

281 ruction; 36 of these women (87.8%) underwent mastectomy with reconstruction.

282 similar after breast conservation and after mastectomy with reconstruction.

283 3 mastectomy without reconstruction, and 222 mastectomy with reconstruction.

284 ast conservation therapy and those receiving mastectomy with reconstruction.

285 Mastectomy only and mastectomy with reconstruction.

286 5%) had a calculated treatment preference of mastectomy with reconstruction; 36 of these women (87.8%

287 procedures: partial mastectomy (PM), partial mastectomy with sentinel lymph node biopsy (PM SLNB), la

288 hout sentinel lymph node biopsy, and partial mastectomy with sentinel lymph node biopsy.

289 ipple-sparing mastectomy (NSM) or (2) simple mastectomy with subsequent nipple reconstruction (SNR).

290 l cohort included 15,154 women who underwent mastectomy with tissue expander (TE: 70.5%), autologous

291 e were 2983 patients who underwent segmental mastectomy with whole-breast irradiation from 1987 to 20

292 f stage 0 to III who were undergoing partial mastectomy, with or without resection of selective margi

293 She underwent partial mastectomy, with partial axillary node dissection and se

294 of overall morbidity in the group undergoing mastectomy without breast reconstruction (odds ratio [OR

295 mplete sample (OR, 0.59; 95% CI, 0.49-0.71), mastectomy without breast reconstruction (OR, 0.59; 95%

296 er overall morbidity in the group undergoing mastectomy without breast reconstruction (OR, 0.61; 95%

297 overall morbidity in the patients undergoing mastectomy without breast reconstruction and in those un

298 Of 85,851 women, 66,593 (77.6%) underwent mastectomy without breast reconstruction, with 2876 (4.3

299 963 underwent breast-conserving surgery, 263 mastectomy without reconstruction, and 222 mastectomy wi

300 laparoscopic inguinal hernia repair, partial mastectomy without sentinel lymph node biopsy, and parti